CohBar Has Received A Notice Of Allowance For Its U.S. Patent Application Titled "THERAPEUTIC PEPTIDES (FOR THE TREATMENT OF METABOLIC DISEASE, CANCER, LIVER DISEASE, AND METHODS OF MODULATING FATTY ACID METABOLISM)"
Portfolio Pulse from Benzinga Newsdesk
CohBar has received a Notice of Allowance for its U.S. patent application titled 'Therapeutic Peptides (for the treatment of metabolic disease, cancer, liver disease, and methods of modulating fatty acid metabolism)'. This could potentially strengthen the company's intellectual property portfolio and provide a competitive edge in the market.
July 19, 2023 | 5:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The Notice of Allowance for CohBar's patent application could potentially strengthen its intellectual property portfolio and provide a competitive edge in the market. This could have a positive impact on the company's stock in the short term.
The approval of a patent application is a significant milestone for any company, as it provides legal protection for their intellectual property. This could potentially give CohBar a competitive edge in the market, which could positively impact the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100